National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Viral Hepatitis



CDC's Response to the Viral Hepatitis/Opioid Syndemic

A Blythe Ryerson, PhD, MPH Associate Director for Science

Caring Ambassadors Syndemic Roundtable May 17, 2018

Presentation Outline

- Overview of CDC
- Addressing the syndemic
 - Surveillance & research
 - Build state, local, and tribal capacity
 - Support providers, health systems, and payers
 - Build partnerships
 - Empower consumers
- Public health policy

CDC

The Nation's Public Health Agency

CDC

- CDC is the nation's health protection agency, working 24/7 to protect America from health and safety threats, both foreign and domestic.
- CDC increases the health security of our nation.



CDC's Role



- Detect and respond to new and emerging health threats
- Tackle big health problems causing death and disability
- Put science and technology into action to prevent disease
- Promote healthy and safe behaviors, communities, and environment
- Develop leaders and train the public health workforce
- Take the health pulse of our nation

CDC Organization

Center for Global Health

National Institute for Occupational Safety & Health

Office of Public Health Preparedness & Response

Office for State, Tribal, Local, & Territorial Support

Office of Public Health Scientific Services



CDC Organization


Center for Global Health

National Institute for Occupational Safety & Health

Office of Public Health Preparedness & Response

Office for State, Tribal, Local, & Territorial Support

Office of Public Health Scientific Services




Prevention & Control

CDC's Response


Interconnected Viral Hepatitis/Opioid Epidemics

Interconnected Epidemics

Drug overdose death rates




Reported new HCV infections



Source: CDC, NCHS Data Visualization Gallery, 2015; CDC, National Notifiable Disease Surveillance System, 2013-2014

CDC Strategy




Surveillance & Research

Surveillance & Research

- Understand the viral hepatitis/opioid syndemic
- Collect timely, actionable data
- Focus prevention efforts




Rise in Opioid-Related Deaths



Source: National Vital Statistics System Mortality File


Lower U.S. Life Expectancy

12 Leading causes of death (ranked highest to lowest according to No. of deaths in year 2015)




Source: Dowell et al., 2017


Acute Hepatitis C Infections Continue to Soar



Hepatitis A Infections Recently on the Rise



Acute Hepatitis B Infections Slightly Decline




Prevention Research

- Study to reduce hepatitis infections by treatment and integrated prevention services (Hepatitis-TIPS) among nonurban persons who inject drugs (PWID)
- Collaboration with NIDA to fund new studies of opioid abuse in non-urban US and the risks for HBV, HCV, HIV, and STIs
- PCORI study of patient-centered modules or HCV care for PWID

Modeling

- Small-area estimates of HCV prevalence
- Estimating the impact of curative HCV treatment on transmission
- Cost effectiveness of syringe services programs (SSPs)
- Expected impact of prescription opioids on viral hepatitis prevalence
- Impact of selected interventions on projected rates of injection-drug use



Build State, Local, and Tribal Capacity

Build State, Local, & Tribal Capacity


- Implement evidence-based interventions
- Conduct community planning and capacity building
- Establish elimination programs
- Conduct Epi-Aid investigations



Improving Hepatitis B & C Care Cascades

- Funding 46 states and 4 jurisdictions
 - Jurisdiction-wide assessment of hepatitis B & C burden
 - Assessment of policies impacting testing, care, and treatment
 - Identify and describe high-burden areas
 - Identify partner sites/organizations for interventions to increase testing
 - Implementation of interventions in 3 priority partner sites

Viral Hepatitis Elimination as a Public Health Threat



Hazard, KY

- NIDA/NCI/CDC
- Preparation phase
- SSP start up (NIDA-funded)
- Increase capacity to provide medication-assisted treatment (MAT)
- Increase capacity to treat HCV

Community Planning and Capacity Building

NACCHO-led work

- Lenowisco Health District, SW Virginia: developed comprehensive outbreak response plan for viral hepatitis and/or HIV among PWID and establish state's first brick and mortar and mobile SSPs
- Kentucky River District: engage community partners around HCV elimination
- Huntington, WV: Re-build community support and buy-in for SSPs



Perinatal Hepatitis B Prevention Programs

- Fund GA, MI, NYC, Philly, and WI to:
 - Improve identification of HBsAg-positive pregnant women (baseline: 47%)
 - Improve rates of PVST among infants born to HBsAg-positive pregnant women (baseline: 63%)
 - Collect demographic and clinical data regarding HBsAg-positive pregnant women and their infants




Outbreaks of hepatitis A in multiple states among people who use drugs and people who are homeless



- Since March 2017, CDC has been providing technical assistance for hepatitis A outbreaks in Kentucky, Michigan, Indiana, California, and Utah
 - Primarily among persons who use injection and non-injection drugs, homeless persons, and their close contacts
 - More than 2,300 cases and 51 deaths
- CDC has provided epidemiology and lab support, testing more than 1,600 specimens, and supporting vaccine policy development and supply

Determination of Need



Source: Van Handel et al., 2016

Support Providers, Health Systems, and Payers

Support Providers, Health Systems, & Payers

- Develop, implement, & evaluate clinical guidelines
- SSP implementation, training, and advocacy toolkit
 - Harm reduction coalition and webinar
 - Implementation plan, communications materials, and evaluation tools
- FOA 1702-Work with SSPs, FQHCs, correctional facilities, and other community-based organizations to identify, treat and engage PWID



Testing algorithms

Clinical Guidelines



Prevention and Control of Infections with Hepatitis
Viruses in Correctional Settings

INSIDE: Continuing Education Examination

CENTERS FOR DISEASE CONTROL AND PREVENTION
SAFER - HEALTHIER - PEOPLE*



Morbidity and Mortality Weekly Report

Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices



commendations and Reports May 19, 2006 / Vol. 55 / No. RR-7

Prevention of Hepatitis A Through Active or Passive Immunization

Recommendations of the Advisory Committee on Immunization Practices (ACIP)





INSIDE: Continuing Education Examination

DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION



MMWR
Markidity and Martality Weekly Report

Recommendations and Reports

September 19, 2008 / Vol. 57 / No. RR-8

Morbidity and Mortality Weekly Report

Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection

Centers for Disease Control and Prevention



Morbidity and Mortality Weekly Report

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016



Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965



Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.htm



U.S. Department of Health and Human Services Centers for Disease Control and Prevention The state of the s



U.S. Department of Health and Human Serv

Clinical Tools


Interpretation of Results of Tests for Hepatitis C Virus (HCV) Infection and Further Actions



TEST OUTCOME	INTERPRETATION	FURTHER ACTIONS
HCV antibody nonreactive	No HCV antibody detected	Sample can be reported as nonreactive for HCV antibody. No further action required.
		If recent exposure in person tested is suspected, test for HCV RNA.*
HCV antibody reactive	Presumptive HCV infection	A repeatedly reactive result is consistent with current HCV infection, or past HCV infection has resolved, or biologic false positivity for HCV antibody. Test for HCV RNA to identify currinfection.
HCV antibody reactive, HCV RNA detected	Current HCV infection	Provide person tested with appropriate counseling and link person tested to care and treatment.†
HCV antibody reactive, HCV RNA not detected	No current HCV infection	No further action required in most cases. If distinction between true positivity and biologic false positivity for HCV antibody is desin and if sample is repeatedly reactive in the initial test, test with another HCV antibody assay
		In certain situations 5 follow up with HCV RNA testing and appropriate counseling.

- * If HCV RNA testing is not feasible and person tested is not immunocompromised, do follow-up testing for HCV antibody to demonstrate seroconversion. If the person tested is immunocompromised, consider testing for HCV RNA.
- † It is recommended before initiating antiviral therapy to retest for HCV RNA in a subsequent blood sample to confirm HCV RNA positivity.
- if the person tested is suspected of having HCV exposure within the past 6 months, or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.

Source: CDC. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR 2013;62(18).



^{*} For persons who might have been exposed to HCV within the past 6 months, testing for HCV RNA or follow-up testing for HCV antibody is recommended. For persons who are immunocompromised, testing for HCV RNA can be considered.

Source: CDC. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR 2013;62(18).

¹ To differentiate past, resolved HCV infection from biologic false positivity for HCV antibody, testing with another HCV antibody assay can be considered. Repeat HCV RNA testing if the person tested is suspected to have had HCV exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.

Build Partnerships

Build partnerships

- Viral hepatitis partners
- Corrections
- Public safety



Traditional Viral Hepatitis Partners



















Correctional Facilities – A Key Partnership

- Test to detect infections
 - PWID are concentrated in corrections due to legal penalties for IDU
 - HCV seroprevalence is estimated as high as 44% in some jurisdictions
 - Universal testing is needed
- Treat
 - Treatment as prevention in corrections and in community after release
- Prevent transmission
 - Syringe services, MAT, HCV cure
- Contribute to overall HCV elimination
 - Corrections accounts for ~1/3 of the HCV burden nationwide



Empower Consumers


Empower consumers

- Public education materials
- Public Service Announcements (PSAs)
- Patient education fact sheets
- Online risk assessment tools



Public Education Materials









HEPATITIS B









疾病防治中心建議您





LOVING YOUR FAMILY STARTS WITH GETTING A HEPATITIS B BLOOD TEST.

YÊJ THƯƠNG GIA ĐÌNH BẮT ĐẦU VỚI VIỆC THỬ NGHIỆM MÁU VE VIỆM GAN B.


B형간염혈액검사,


57.88.55 (HCM) 0909.18.66.66

do Viêm Gan B

Viral Hepatitis Online Risk Assessment Tool

- Online tool to assess risk for hepatitis A, B, and/or C
- http://www.cdc.gov/hepatitis/RiskAssessment/







Intersection of Public Health and Policy

Harm reduction is vital to viral hepatitis prevention

Counties at risk for HIV & HCV outbreaks among PWID




SSP coverage – June 2014



Source: Van Handel et al., 2016; AmfAR, 2014

Harm reduction is vital to viral hepatitis prevention


HCV cases among persons aged 15-29 years and SSPs, July 2015-June 2016



Source: Canary et al., 2015

Harm reduction is vital to viral hepatitis prevention

Comprehensiveness of state laws pertinent to prevention of HCV infection among PWID; US, 2016



Source: Campbell et al., 2017

Acknowledgements

- Alice Asher
- Alyson Rose-Wood
- Cecily Campbell
- Liesl Hagan
- Noele Nelson
- Sarah Schillie

- Aaron Harris
- Cynthia Jorgensen
- Melissa Collier
- Eyasu Teshale
- Rachel Wilson
- Monique Foster

Contact Information

A Blythe Ryerson, PhD, MPH Aryerson@cdc.gov

For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

